FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease

FIDELIO-DKD: Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Rationale : Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in patients with type 2 DM. Long term efficacy and safety in terms
of renal and cardiovascular outcomes remains unknown.

Infographic

Reference

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229.

About the author 

MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


Videos

  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates
>